REG-Arix Bioscience PLC Unaudited NAV for April

Arix BioscienceAnnouncement

11/05/2022 07:15

============

   Arix Bioscience PLC (ARIX)
   Unaudited NAV for April

   11-May-2022 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                                        

   PRESS RELEASE

                              Arix Bioscience plc

                                        

                            Unaudited NAV for April

    

   LONDON, 11 May 2022: Arix Bioscience  plc (“Arix” or the “Company”)  (LSE:
   ARIX),  a  global  venture  capital   company  focused  on  investing   in
   breakthrough biotechnology companies, announces  the unaudited NAV of  the
   Company for date ended 30 April 2022 as follows:

    

    

                               NAV Breakdown                              
      Date                                                     Total
                Listed   Unlisted Portfolio  Cash     Other     NAV   NAV per
               Portfolio                            Interests          share
                                                                       
    30-Apr-22
                £36.3m         £57.7m       £132.6m   £2.8m   £229.4m  £1.78
   (unaudited)
                                                                          

    

                                      ENDS 

    

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  NAV
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   160805
   EQS News ID:    1348823


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1348823&application_name=news&site_id=refinitiv2

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1348823&site_id=refinitiv2&application_name=news


============